Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment

Jianfeng Lu, Donna McEachern, Haiying Sun, Longchuan Bai, Yuefeng Peng, Su Qiu, Rebecca Miller, Jinhui Liao, Han Yi, Meilan Liu, Anita Bellail, Chunhai Hao, Shi Yong Sun, Adrian T. Ting, Shaomeng Wang

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Smac mimetics are being developed as a new class of anticancer therapies. Because the single-agent activity of Smac mimetics is very limited, rational combinations represent a viable strategy for their clinical development. The combination of Smac mimetics with TNF-related apoptosis inducing ligand (TRAIL) may be particularly attractive because of the low toxicity of TRAIL to normal cells and the synergistic antitumor activity observed for the combination. In this study, we have investigated the combination synergy between TRAIL and a potent Smac mimetic, SM-164, in vitro and in vivo and the underlying molecular mechanism of action for the synergy. Our study shows that SM-164 is highly synergistic with TRAIL in vitro in both TRAIL-sensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer. Furthermore, the combination of SM-164 with TRAIL induces rapid tumor regression in vivo in a breast cancer xenograft model in which either agent is ineffective. Our data show that X-linked IAP (XIAP) and cellular IAP 1 (cIAP1), but not cIAP2, work in concert to attenuate the activity of TRAIL; SM-164 strongly enhances TRAIL activity by concurrently targeting XIAP and cIAP1. Moreover, although RIP1 plays a minimal role in the activity of TRAIL as a single agent, it is required for the synergistic interaction between TRAIL and SM-164. This study provides a strong rationale to develop the combination of SM-164 and TRAIL as a new therapeutic strategy for the treatment of human cancer.

Original languageEnglish (US)
Pages (from-to)902-914
Number of pages13
JournalMolecular Cancer Therapeutics
Volume10
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Neoplasms
Therapeutics
SM 164
Breast Neoplasms
Heterografts
Colonic Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. / Lu, Jianfeng; McEachern, Donna; Sun, Haiying; Bai, Longchuan; Peng, Yuefeng; Qiu, Su; Miller, Rebecca; Liao, Jinhui; Yi, Han; Liu, Meilan; Bellail, Anita; Hao, Chunhai; Sun, Shi Yong; Ting, Adrian T.; Wang, Shaomeng.

In: Molecular Cancer Therapeutics, Vol. 10, No. 5, 01.05.2011, p. 902-914.

Research output: Contribution to journalArticle

Lu, Jianfeng ; McEachern, Donna ; Sun, Haiying ; Bai, Longchuan ; Peng, Yuefeng ; Qiu, Su ; Miller, Rebecca ; Liao, Jinhui ; Yi, Han ; Liu, Meilan ; Bellail, Anita ; Hao, Chunhai ; Sun, Shi Yong ; Ting, Adrian T. ; Wang, Shaomeng. / Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 5. pp. 902-914.
@article{01b2d862580348de97f13579c7e739cf,
title = "Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment",
abstract = "Smac mimetics are being developed as a new class of anticancer therapies. Because the single-agent activity of Smac mimetics is very limited, rational combinations represent a viable strategy for their clinical development. The combination of Smac mimetics with TNF-related apoptosis inducing ligand (TRAIL) may be particularly attractive because of the low toxicity of TRAIL to normal cells and the synergistic antitumor activity observed for the combination. In this study, we have investigated the combination synergy between TRAIL and a potent Smac mimetic, SM-164, in vitro and in vivo and the underlying molecular mechanism of action for the synergy. Our study shows that SM-164 is highly synergistic with TRAIL in vitro in both TRAIL-sensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer. Furthermore, the combination of SM-164 with TRAIL induces rapid tumor regression in vivo in a breast cancer xenograft model in which either agent is ineffective. Our data show that X-linked IAP (XIAP) and cellular IAP 1 (cIAP1), but not cIAP2, work in concert to attenuate the activity of TRAIL; SM-164 strongly enhances TRAIL activity by concurrently targeting XIAP and cIAP1. Moreover, although RIP1 plays a minimal role in the activity of TRAIL as a single agent, it is required for the synergistic interaction between TRAIL and SM-164. This study provides a strong rationale to develop the combination of SM-164 and TRAIL as a new therapeutic strategy for the treatment of human cancer.",
author = "Jianfeng Lu and Donna McEachern and Haiying Sun and Longchuan Bai and Yuefeng Peng and Su Qiu and Rebecca Miller and Jinhui Liao and Han Yi and Meilan Liu and Anita Bellail and Chunhai Hao and Sun, {Shi Yong} and Ting, {Adrian T.} and Shaomeng Wang",
year = "2011",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-10-0864",
language = "English (US)",
volume = "10",
pages = "902--914",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment

AU - Lu, Jianfeng

AU - McEachern, Donna

AU - Sun, Haiying

AU - Bai, Longchuan

AU - Peng, Yuefeng

AU - Qiu, Su

AU - Miller, Rebecca

AU - Liao, Jinhui

AU - Yi, Han

AU - Liu, Meilan

AU - Bellail, Anita

AU - Hao, Chunhai

AU - Sun, Shi Yong

AU - Ting, Adrian T.

AU - Wang, Shaomeng

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Smac mimetics are being developed as a new class of anticancer therapies. Because the single-agent activity of Smac mimetics is very limited, rational combinations represent a viable strategy for their clinical development. The combination of Smac mimetics with TNF-related apoptosis inducing ligand (TRAIL) may be particularly attractive because of the low toxicity of TRAIL to normal cells and the synergistic antitumor activity observed for the combination. In this study, we have investigated the combination synergy between TRAIL and a potent Smac mimetic, SM-164, in vitro and in vivo and the underlying molecular mechanism of action for the synergy. Our study shows that SM-164 is highly synergistic with TRAIL in vitro in both TRAIL-sensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer. Furthermore, the combination of SM-164 with TRAIL induces rapid tumor regression in vivo in a breast cancer xenograft model in which either agent is ineffective. Our data show that X-linked IAP (XIAP) and cellular IAP 1 (cIAP1), but not cIAP2, work in concert to attenuate the activity of TRAIL; SM-164 strongly enhances TRAIL activity by concurrently targeting XIAP and cIAP1. Moreover, although RIP1 plays a minimal role in the activity of TRAIL as a single agent, it is required for the synergistic interaction between TRAIL and SM-164. This study provides a strong rationale to develop the combination of SM-164 and TRAIL as a new therapeutic strategy for the treatment of human cancer.

AB - Smac mimetics are being developed as a new class of anticancer therapies. Because the single-agent activity of Smac mimetics is very limited, rational combinations represent a viable strategy for their clinical development. The combination of Smac mimetics with TNF-related apoptosis inducing ligand (TRAIL) may be particularly attractive because of the low toxicity of TRAIL to normal cells and the synergistic antitumor activity observed for the combination. In this study, we have investigated the combination synergy between TRAIL and a potent Smac mimetic, SM-164, in vitro and in vivo and the underlying molecular mechanism of action for the synergy. Our study shows that SM-164 is highly synergistic with TRAIL in vitro in both TRAIL-sensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer. Furthermore, the combination of SM-164 with TRAIL induces rapid tumor regression in vivo in a breast cancer xenograft model in which either agent is ineffective. Our data show that X-linked IAP (XIAP) and cellular IAP 1 (cIAP1), but not cIAP2, work in concert to attenuate the activity of TRAIL; SM-164 strongly enhances TRAIL activity by concurrently targeting XIAP and cIAP1. Moreover, although RIP1 plays a minimal role in the activity of TRAIL as a single agent, it is required for the synergistic interaction between TRAIL and SM-164. This study provides a strong rationale to develop the combination of SM-164 and TRAIL as a new therapeutic strategy for the treatment of human cancer.

UR - http://www.scopus.com/inward/record.url?scp=79956006296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956006296&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0864

DO - 10.1158/1535-7163.MCT-10-0864

M3 - Article

C2 - 21372226

AN - SCOPUS:79956006296

VL - 10

SP - 902

EP - 914

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -